PolyPid Ltd.

NASDAQ:PYPD

Biotechnology

Healthcare
$6.56 +8.23%

+$0.39 today

Market cap
$133.25M
Beta
1.43
P/E (TTM)
-2.7
EPS (TTM)
-$1.53
52W Low $3.06High $5.21

Volume 0.30M

Average 0.09M

PYPD Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

PolyPid Ltd.NASDAQ: PYPD

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 299.7% from a year ago

Cash & equivalents stood at $9.08M at the end of Q1 FY2026, up 299.7% from a year earlier and up 41.9% from the prior quarter. Over 3 fiscal years it compounded at -9.2% a year.

Context

  • Cash & equivalents amounted to 47.4% of total assets at the end of Q1 FY2026, up 33.9 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +299.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.08M+41.9% QoQ
Last fiscal yearDec 2025
$6.4M-59.1% YoY
Year agoMar 2025
$2.27M+299.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+299.7%——
1 year-59.1%——
3-year CAGR-9.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
6.4M USD
Year-over-year change
-59.1%
4-year CAGR
-10.1%

Cash & Equivalents vs competitors

How PYPD compares with its peers on the latest reported figures

  • PYPD's Mar 2026 cash & equivalents of $9.08M is the 6th highest of the 7 companies compared; the peer median is $24.63M.
  • Its year-over-year change of +299.7% is the 2nd highest of 7, against a peer median of +0.9%.
  • Cash & equivalents amounts to 47.4% of total assets for PYPD, versus a peer median of 87.7%.
PYPD Competitors Peer median
Cash & Equivalents for PYPD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ATNMActinium Pharmaceuticals, Inc.Jun 2026$36.47M -39.1%-23.9%90.8%
MAIAMAIA Biotechnology, Inc.Mar 2026$34.41M +216.8%+824.7%97.4%
VERUVeru Inc.Mar 2026$27.6M +37.9%-41.8%64.1%
PDSBPDS Biotechnology CorporationMar 2026$21.66M -45.8%-28.7%87.8%
ANVSAnnovis Bio, Inc.Mar 2026$14.22M -36.1%-11.7%87.5%
PYPDPolyPid Ltd.Mar 2026$9.08M +299.7%-9.2%47.4%
CELUCelularity Inc.Dec 2025$6.18M +736.7%-23.8%5.8%
Peer median (excluding PYPD) $24.63M+0.9%-23.9%87.7%

Competitors are the stored peer set for PYPD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents9.82M8.55M5.61M15.64M6.4M
Short-term Investments22.38M4.04M006.53M
Net Receivables118K298K000
Inventory00001.11M
Other Current Assets993K750K106K602K193K
Total Current Assets34.81M14.19M6.07M16.57M15.23M
Property, Plant & Equipment (Net)8.76M11.68M9.22M8.37M6.77M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets663K99K87K277K311K
Total Non-current Assets9.42M11.78M9.31M8.65M7.08M
Total Assets44.24M25.97M15.37M25.22M22.31M
Account Payables4.14M1.14M772K2.41M2.86M
Short-term Debt04.02M4M6.79M988K
Tax Payables00000
Deferred Revenue269K0000
Other Current Liabilities016K1.01M23K0
Total Current Liabilities8.08M8.55M7.29M12.68M7.74M
Long-term Debt07.57M6.38M634K0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)02.55M2.55M2.55M0
Other Non-current Liabilities199K294K398K396K2.95M
Total Non-current Liabilities199K11.59M10.18M4.86M3.6M
Total Liabilities8.28M20.14M17.47M17.54M11.33M
Common Stock00000
Retained Earnings(174.89M)(214.44M)(238.31M)(267.33M)(301.5M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity35.96M5.83M(2.1M)7.68M10.97M
Total Debt013.73M11.78M9.62M2.8M
Net Debt(9.82M)5.18M6.17M(6.02M)(3.61M)

PolyPid Ltd.

NASDAQ:PYPD

Intrinsic Alpha fair value

Locked

Current Price

$6.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.